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Preface 
The elective period we as medical students have in January our second year is a rare 
opportunity to combine the educating process of collecting and reviewing data with the 
extraordinary option of looking at a medical topic through the eyes of another nation. We 
immediately decided that we wanted to use this period to its full extent. Having a bit of a 
rough start with finding contacts abroad, our luck eventually turned when we happened to 
come across a freshly released report on cardiovascular risk and disease in Australian women, 
Hidden Hearts, which Professor Maja-Lisa Løchen at UiT had been a part of. Instantly 
inspired by the subject’s relevance and seriousness, we decided that cardiovascular disease is 
a topic in need of more attention. 
 
Through Professor Løchen we got in contact with Professor Simon Stewart, the inaugural 
Director of the Mary MacKillop Institute for Health Research (MMIHR) located in 
Melbourne, Australia. He arranged for our stay at the MMIHR during our elective month in 
January, and gave us access to data to survey, which were collected by him and his research 
team in advance for the Which Heart failure Intervention is most Cost-effective in reducing 
Hospital care (WHICH?) II trial. Their results and report on the WHICH? II trial is yet to be 
released, but our assignment will to a great extent be based on our analysis of the study cohort 
from this trial - more specifically the participants that face hindrances in maintaining their 
disease because of struggles to attend the existing health services available and/or their ability 
to self-care. 
 
CHF is a condition that affects the heart’s function or structure, resulting in an insufficient 
pumping function and delivery of oxygen to the body, and give rise to a series of typical 
symptoms such as breathlessness and fatigue (1). The aim of this report is to explore as well 
as describe the obstacles and barriers that CHF-patients may face in their managing of the 
disease, and how these complications can affect their outcome. By acknowledging these 
barriers and giving them a character we hope to further the understanding of the complexity 
and uniqueness that each individual case present, and thereby promote the ability to treat 
these cases based on their individual demands. Furthermore, we hope that this report will give 
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some attention to a disease so lacking of awareness and research considering its extreme 
burden on populations and health care systems worldwide (2).  
 
The WHICH? II trial (from which our data is collected) is financed by the National Health 
and Medical Research Council Project Grant (2013 - 2016) number 1049133. Lånekassen also 
contributed with financial support to our project. 
 
We would like to thank our supervisor Tor Brynjar Stuge, for always being available for 
questions and for guiding us on our assignment whenever needed. We would also like to show 
gratitude to Professor Maja-Lisa Løchen, for helping us with getting in contact with the 
institute that has given us such an educational value. 
 
A special thanks to the whole research team and staff at the MMIHR for taking us in with an 
extraordinary openness and hospitality, and for their vital help and guidance before, during 
and after our stay with them. Most importantly we wish to express our sincere thanks to 
Professor Simon Stewart who has motivated, inspired and guided us with his immense 
knowledge, and dedicated his time, energy and support throughout this whole experience.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tromsø, 27.02.2017 
 
                                                   
         Grethe Aune                                                                           Vilde Dragland  
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Abstract 
Background: Chronic heart failure (CHF) is one of the most mortal and disabling of 
cardiovascular disease (CVD) syndromes, and represents an international health problem. 
However, there is currently a lack of awareness and research surrounding the disease, which 
results in an insufficient understanding of both the nature of the illness as well as the 
managing of it. 
 
Objective: To describe and increase the awareness of specific barriers to care a CHF patient 
may experience - reporting their commonness, severity and expected consequences. 
 
Material and methods: Patients were recruited by research teams for the WHICH? II trial - 
recruitment beginning 1st of July 2013 and completed the 31st of January 2016. A baseline 
profile from all the eligible participants was collected by applying a combination of extensive 
self-report and review of patient records (also conducted by the same research team), and the 
following analysis and characterization of the study population we carried out was done using 
the statistical program SPSS. In addition, there was conducted a supplementary literary study. 
 
Results: Amongst the study cohort there was an obvious presence of barriers that could 
hinder the patient in effective managing of their health and disease. We identified and 
described five of these barriers: living remote from health care services, age in the upper 
quartile (83+), cognitive impairment and/or language barrier, living alone, NYHA class III or 
IV. Due to this observable and evident presence one can describe the barriers surveyed as 
common and with high frequency amongst CHF patients. All of the barriers had a high 
prevalence, and the least common barrier still was present in around ¼ of the study cohort. 
All of these barriers can also be viewed as possible roots for complications in the patients 
maintaining of good health and disease management. Looking at the existing knowledge 
regarding each individual barrier, it is obvious that these factors have a high potential risk of 
affecting the patient’s ability to manage their own health and condition. 
 
Conclusions:  
The barriers to health care described can despite their variations all be characterized as 
common hindrances for the typical CHF patient. Some of the individual barriers vary in 
severity and therefore also in their potential risks and likelihood.  
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Abbreviations 
 
CVD; Cardiovascular disease(s) 
CBI; Clinical-based intervention  
CHF; Chronic heart failure 
CHF-MP; Chronic heart failure managing programs  
HBI; Home-based intervention  
MMIHR; Mary MacKillop Institute for Health Research  
MoCA; Montreal Cognitive Assessment 
NYHA; New York Heart Association 
SPSS; Social Sciences Statistical Package  
WHICH?; trial Which Heart failure Intervention is most Cost-effective in reducing Hospital 
care trial  
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Introduction 
Cardiovascular disease  
Cardiovascular disease is used to describe all the diseases and conditions that have an effect 
on the heart and blood vessels of the body (3, s.3). Currently regarded as a major cause of 
death, as well as a leading burden of disease, we could consider the term as highly relevant on 
a global scale. Presented by the World Health Organization, data from 2012 estimate that 31 
% of all deaths worldwide were CVD-related, corresponding to a total of 17.5 million people 
(4). Despite a still high rate, the overall mortality seems to have declined since its peak in the 
late 1960s, partly due to increased focus on prevention, but also as a consequence of 
improved treatment methods, detections and research on the area (3, s.4-5). Having said that, 
improved survival of patients, along with an ageing population in most developed countries, 
results in a greater amount of individuals who have to live with a cardiovascular condition, 
and therefore an expanded burden both globally and for individual nations. 
 
One of the conditions that is considered to contribute to a larger pool of CVD patients in the 
future, and therefore attributable to an increased burden of heart disease worldwide, is chronic 
heart failure (2). Based on these expectations, it is beyond any doubt a need to further 
improve health care services and follow-up of this particular group of patients.   
	
What is chronic heart failure (CHF)?  
Chronic heart failure (CHF) is a long-term, life-threatening disease which primarily affect 
elderly individuals (5). Considered as a complicated condition with a set of underlying causes, 
symptoms and characterizations, it can be viewed as a complex clinical syndrome (6). Despite 
highly variable differences regarding their state, a common hallmark for the majority of CHF-
patients is an abnormal ejection or filling phase carried out by the left ventricle of the heart, 
resulting in an insufficient blood stream to the rest of the body (1). Most frequently, this 
situation is caused by a structural abnormality or cardiac dysfunction from protracted 
hypertension, diabetes, dilated cardiomyopathy or other cardiovascular conditions (7, s.12).  
 
There are two main forms of CHF. The first one is known as systolic heart failure which 
means that ability to pump blood to the rest of the body is reduced. The other form is 
	 2	
recognized by an abnormal relaxation of the heart, referred to at diastolic dysfunction (8). 	
	
The current situation of CHF  
Despite improved treatment of cardiovascular disease since the 1960s, the prognosis of CHF 
patients is still considered as poor, with 5-year survival rate still under 50 % in most age-
groups (9).  
 
One of the countries that currently face a major challenge of heart disease, especially 
regarding a major CHF-burden, is Australia. Numbers from 2011, show that CHF as a cause 
of death contributed to 13 % of the overall mortality (10), a rate which highlight the need for 
further research on prevention and improved treatment methods. In addition, as a consequence 
of data indicating that hospitalization account for close to 70 percent of the total HF-related 
costs (11), several studies currently aim to develop management programs which decline the 
frequency and durations of hospital stays in CHF-patients. A recent one, called the WHICH? 
trial, elaborated by the NHMRC centre of research excellence (CRE), emphasized the 
importance of HBI as a source to reduced health costs by comparing it to a CBI on patients 
receiving a post-discharge CHF-MP.  
 
On one hand, the WHICH? trial illustrates the need for an extended focus on home-visits 
rather than seeing hospitals as the exclusive treatment arena for post-discharge CHF-patients. 
On the other hand, this trial applied a “one size fits all” model. In aiming to further improve 
poor outcomes in CHF by developing a cost-effective individualized program, it is important 
to be aware of the barriers each patient may face.  
Barriers to health care 
In this report, the term barrier refers to “any factor that can be seen as a hindrance for disease 
management, including access to health-services and/or the ability to self-care”. 
 
An obvious barrier in disease management is distance to health care services. The majority of 
post-discharge CHF-patients are dependent on continuous management (12), and their 
geographical location could therefore be seen as a hindrance, as it influence the ability to 
readily access the services and resources needed to take care of their health (13-15). An 
ongoing study, which is yet to be published, called the WHICH? II trial, was both initiated as 
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a response to the ”one size fits all” model, but also with an aim to put a light on management 
in remote areas (16, 17). In this, the NHMRC CRE explore the outcome of a more individual 
approach to post-discharge CHF-management, and at the same time the advantages of 
telephone support to people living in regional Australia (18).  
 
In addition to distance, there are several other barriers in need of attention. One recent study 
elaborated in Australia in 2015 claimed that personal, sociodemographic and health 
characteristics are important factors in order to prevent hospitalisations (19), and it is 
therefore important to look at some of these factors. One widely discussed and highly relevant 
is the age among CHF-patients. As a part of the natural biological changes from birth to old, 
including weakened muscle strength, hearing and vision, we could assume that the ability to 
self-care and accessing hospitals may be reduced. Moreover, many elderlies are affected by 
multiple diseases in addition to CHF (20), which make the disease management even more 
challenging. Although it is hard to do something about the development in age pattern, it is 
important to be aware of the individual hindrances these patients may face in order to come 
up with well-established prevention methods. This is particularly relevant these days 
considering the current situation in many countries, including in Australia. 
 
Due to a tendency of decline in mortality and fertility among the Australian population since 
the 1960s (21), the life expectancy at birth between 2011-2013 was stated to be 80.1 years 
among men and 84.4 among females, compared to 67,9 and 74,2 in 1960-62 (22). As a 
consequence of an older population, as well as data indicating that the prevalence of CHF 
increase remarkably by age (23), a great amount of individuals, and mostly elderly, are living 
with the syndrome. Based on both the magnitude of elderly CHF-patients and their variety of 
obstacles, we could claim that it is beyond any doubt important to describe this barrier.  
 
Two other factors that can be seen as impediments to disease management are the severity of 
CHF-symptoms and cognitive impairment. Firstly, the most important CHF-symptoms are 
breathlessness, fatigue and ankle swelling (24). One of the standardized test used to measure 
breathlessness, is the NYHA score (described in material and methods), which among others 
could be used to indicate to what degree the patient is able to take care of their health and 
disease. Secondly, cognitive impairment (here defined as having a MoCA score ≤ 23), which 
range from mild to severe, include reduced ability to remember, learn and concentrate (25). 
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These factors, especially on a severe level, could be seen as an obstacle in management and 
awareness of the disease.  
 
Combined with other barriers, an additional one is whether or not the patient lives alone. A 
lack of network while having other complications, such as increased age, cognitive 
impairment and/or NYHA class III or IV, could lead to even more complex challenges 
concerning self-care, including awareness of CHF danger-signs, and also the ability to access 
hospital when needed. 
 
It is important to highlight that it is a set of barriers to care, including the ones mentioned 
above. However, in this assignment we have chosen to focus on these factors due to its 
relevance and their consequences in the development of the disease. A more detailed 
definition of the variables can be viewed in the material and methods section. 
Aim 
To describe and increase the awareness of specific barriers to care a CHF patient may 
experience - reporting their commonness, severity and expected consequences. 
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Material and methods 
This report is based on data obtained through varying methods: a literary study done prior, 
throughout and subsequent to our stay at the MMIHR, the reception of a portion of the 
WHICH? II trial results, and an analysis of said results. 
Literature 
The literature utilized in this report were collected mainly from two sources; PubMed (U.S 
National Library of Medicine National Institutes of Health), and articles either published or 
recommended by the research team and staff at the MMIHR and Professor Simon Stewart. 
 
Literature required through PubMed 
Keywords in searching: 
• Cardiovascular disease 
• Heart failure+epidemiology 
• Heart failure+burden 
• Heart failure + heart failure, systolic + heart failure, diastolic  
	
Literature published or recommended by MMIHR 
 
A large proportion of the sources utilized were given to us by the research team and Professor 
Simon Stewart. Some of these articles are yet to be published and/or not available to the 
public, these include: 
• The WHICH? II trial protocol (18) 
• Barriers to care (Ahamed Y, Chan Y, Crystal LJ et al. Manuscript submitted for 
publication.) 
Study design 
The data analysed and presented in the results were collected prior and separate to our 
involvement, and was executed in correlation with the WHICH? II trial - a randomised 
controlled trial. Only a selected portion of the study population originally recruited were used 
in our analysis (specified further down). 
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Study population 
Recruitment 
The recruiting of participants for WHICH? II trial began the 1st of July 2013 and was 
complete the 31st of January 2013. Patients admitted to five different hospitals situated in 
various locations were screened for eligibility by research teams. 
Selection criteria 
Inclusions: Patients aged ≥ 18 years discharged from hospital, diagnosed with CHF and with 
a history of ≥ 1 admission for acute decompensated heart failure (including the index event). 
Exclusions: Presence of a terminal condition and/or incapable of providing fully informed 
consent. Patients living in or being admitted to nursing homes were also excluded. 
Ethical aspects 
All participants of the WHICH? II trial gave written informed consent to take part of the trial. 
This consent also involves the approval of using their data for research and analysis outside of 
the WHICH II trial, such as the ones conducted in this report. 
	
Baseline profiling 
 
A baseline profile was established for all qualified participants by extensive self-report and 
review of patient records. This profiling were conducted by a research team involved in the 
WHICH II trial, and the questionnaire used was developed without any of our involvement. 
We analyzed only a limited portion of the baseline details obtained, as these were the ones we 
judged to be relevant for our report. The participants were analysed and characterized based 
on the answers on these questions. 
Analysis of the collected data 
The following data collected were analysed by the use of SPSS, and the results were 
converted to figures, tables and charts. The analysis was done during our stay at the MMIHR, 
and in total 13 days were spent at the institute working with the data. All of the finished 
results were assessed by the research team we collaborated with, to further secure that the 
results in this report did not contain any errors or inaccuracy. Only the participants with 
complete data for the variables reviewed were included in our analysis. 
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Specification on the variables analysed and presented in the results 
The analysis consists of characterizing the participants by the information collected in the 
baseline profiling, and by the help of SPSS we could analyse the commonness and 
combination amongst the barriers. Based on questions from the baseline profiling 
questionnaire we defined five different factors that could act as a hindrance in obtaining 
and/or maintaining good health and disease management for an individual patient; five 
barriers to health care.  
These are as following: 
• Living remote from health care services (remote here defined as living ≥ 25 km from a 
hospital) 
• Age in the upper quartile (83 +)  
• Living alone 
• Impaired cognitive function and/or language barrier 
• NYHA class III or IV at discharge 
Instruments used in measuring variables 
In measuring the subject’s cognitive function the Montreal Cognitive Assessment (MoCA) 
tool (attachment 1) was used, and in this report we define cognitive impairment as having a 
MoCA score ≤ 23. However, in the case of language barriers in the patient it is unclear 
whether a MoCA score ≤ 23 is due to actual cognitive impairment or a result of the language 
barrier, and on account of this a percentage of the participants did not take the MoCA test. In 
defining the barrier as either having impaired cognitive function and/or a language barrier, we 
prevent excluding a significant percentage of the participants. For assessing the patient’s CHF 
symptoms and their severity the New York Heart Association (NYHA) Functional 
Classification System (attachment 2) was used.  
 
By the use of SPSS we could illustrate and thereby describe the commonness and severity as 
well as the correlation among the different barriers. Furthermore, we could describe the 
potential consequences associated with the presence of one or a combination of the barriers, 
by the support of a supplementary literary study. 
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Results 
Description of the study cohort 
In total we analysed 783 patients diagnosed with CHF, and of these patients 323 were female 
and 460 were male. The mean age amongst the women was 77.8 years, while 71.8 years for 
men. The mean age for the whole study cohort independent of sex was 74.3 years. 
 
The upper quartile (75) for men was 81 years and for woman 86 years. For the whole study 
cohort the upper quartile independent of sex was 83 years. 
Prevalence of the barriers to care 
Table 1: Amount and percentages of our selected barriers   
 
                                                                   Prevalence 
	 
 Distance > 
25km 
Age 83+ NYHA class 
III, IV 
MoCa_NES ≤ 
23 
 
 n 
(%) 
n 
(%) 
n 
(%) 
n 
(%) 
Amount of 
study cohort 
146 
(18,6) 
196 
(25) 
224 
(28,9) 
403 
(51,5) 
 
Based on our specification of the variables, 18,6 % of the participants were living remote, 
which correspond to an amount of 146 patients. Looking at the age, one quarter (196) of the 
783 patients were 83 years or older. Moreover, 224 had been considered to be NYHA class III 
or IV at discharge. Lastly, almost half of our study cohort had either cognitive impairment 
and/or a language barrier.   
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Variance  
Table 2: NYHA classification at discharge  
 
                                                         NYHA classification  
 
 Did not 
take the 
test  
I II III IV Total 
 n 
(%) 
n 
(%) 
n 
(%) 
n  
(%) 
n 
(%)  
n 
(%) 
Amount of 
study 
cohort 
2 
(0,3) 
95 
(12,1) 
462 
(59,0) 
211 
(26,9) 
13 
(1,7) 
783 
(100) 
 
Of the 783 participants, two did not take the test for unknown reasons.  More than half of the 
patients were classified as II at discharge, which means that the majority had slight limitation 
in physical activity. Even though a small amount were classified as IV, 211 were considered 
as moderate (III), assumed to have marked limitation of physical activity, which means that 
less than ordinary activity cause shortness of breath, rapid heartbeat and chest pain. 
 
Table 3: Age percentiles  
 
AGE 
 
 Male (M) Female (F) Both 
 Age Age Age 
 
 
25 64 72 67 
Percentiles 50 73 80 77 
 75 81 86 83 
 
Among the 460 male participants, one quarter were under 64 years and 50 % under 71. 
Furthermore, three fourths were 81 years or younger. For female the corresponding numbers 
were 72, 80 and 86 years. In the total study cohort independent of sex, one quarter were over 
83 years, which is our lower limit for the age barrier in this report.   
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Figure 1:  
The combination and prevalence of three barriers (age 83+, NYHA III or IV and 
MOCA_NES ≤ 23) 
	
	
 
 
 
 
 
 
 
Figure 2: 
The combination and prevalence of three barriers (NYHA III or IV, live alone and age 83+) 
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The first venn diagram show the combinations between Age 83+, MoCa_NES (cognitive 
impairment and/or language barrier) and NYHA class III or IV. 71 participants had both and 
age barrier and NYHA class III or IV, while 125 were 83+ and had cognitive impairment 
and/or a language barrier. One hundred and thirty-three of our study cohort were classified as 
moderate (III) or severe (IV) on the NYHA scale in a combination with cognitive impairment 
and/or a language barrier. Moreover, 46 of the patients in our cohort were facing all of the 
three barriers presented. 
The second diagram illustrate the combinations between patients living alone, having NYHA 
class III or IV and aged 83 years or older. Of the 314 participants living alone, 84 were also 
facing an obstacle in breathlessness, having NYHA class III or IV at discharge. One hundred 
and twenty-five of the patients with this particular obstacle were over 83 years. Moreover, 
108 were both old and living alone. Adding all, 33 patients aged over 83 with NYHA class II 
or III were living alone. 
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Discussion 
The results of this study as well as existing knowledge promise a high chance of presence by 
impediments to successful and effective health care in the individual CHF patient. Each of the 
barriers described in this report have a high prevalence amongst our study cohort, and in 
assuming the study cohort represents an accurate representation of the actual population of 
CHF patients, one can describe these barriers as common and widespread.  
 
Having a NYHA class III or IV at discharge was the most common hindering for the 
participants (not including the impaired cognitive function and/or language barrier, as this is a 
barrier combined of two variables), with over ¼ of the participants struggling with 
breathlessness at rest or when doing less than ordinary activity. Not only is this the most 
common impediment present in our study cohort, it is also an impediment that affects their 
quality of life (26), increases the yearly mortality (27), and presumably their ability to manage 
their own health and condition. One can assume that such a disabling symptom as 
breathlessness in resting state or when doing less than ordinary activities will prevent the 
typical patient physically or psychologically from doing regular exercise. Exercise has been 
shown to reduce major cardiac events such as hospitalization and mortality (28), and with an 
absence of regular exercise a patient will also have an absence of its beneficial effects on their 
health and disease. One can also assume that symptoms such as dyspnea, fatigue and 
palpitation at rest or when doing less than ordinary activities will potentially reduce the 
patient's quality of life, as well as reduce their ability to take care of themselves and their own 
health because of the physical activity such tasks demand. 
 
Looking at the variance in age, we saw that 25 % (196) of the study cohort were aged 83 or 
more. Based on our results, 71 of these participants also had NYHA class III or IV, which 
means that around ⅓ of the elderly have struggles when they are in activity. As mentioned, 
this could have an impact on disease management and their ability to improve their condition. 
Moreover, studies suggest that physical activity could reduce hospitalization and mortality 
(28) as well as the likeliness of cognitive impairment (29), which also could be seen as an 
impediment, as mentioned in the introduction part. This is an example of a possible chain 
reaction as an effect of the age, and illustrate the variety of obstacles the elderly have in 
addition to their heart disease.  
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When selecting the barriers to survey we included how many of the participants were living 
alone. However, we chose to combine this variable with one or more of the other variables 
described as barriers to health care, as living alone only complicate maintenance of the 
disease if the patient is affected by other impediments and therefore in need of assistance 
through a cohabitant. Of the 314 participants living alone, around one out of ten had a NYHA 
class III or IV, 13.7 % were in the upper quartile of age and 4.2 % had both of the barriers. 
Having a combination of barriers such as seen here will increase the amount of complications 
in managing their health condition, as each barrier is associated with different sort of 
complications.  
 
There are a few limitations to our report. Due to the lack of research and studies done to the 
current day, a big proportion of the data and statistics presented are not up to date or 
inadequate. In addition, the data collected by self-report may not represent an accurate picture 
of the reality. One of the reasons behind this is that the tools used to grade certain features 
may not always be reliable - in example the MoCA test can be influenced by interfering 
factors, such as the patient’s general health at the time the test was taken. This limitation 
includes other self-reported data that may be subject to inaccuracy because of the subjects 
involvement in assessing their own condition. Also the study cohort surveyed might not 
represent the actual population of CHF patients due to its small size, or the recruitment 
criteria may exclude a big portion as well as include a specific kind of CHF patients that does 
not represent the typical CHF patient. 
 
In addition, there should be a mentioning that in the defining of the barriers we had to 
combine having impaired cognitive function with having a language barrier, to prevent the 
exclusion of a significant percentage of the participants (the complete description on the 
combining of these two barriers can be found under Material and methods). This combining 
of two barriers does however limit the actual and accurate picture of the reality of each 
barrier. It creates a barrier which makes it hard to tackle and describe the actual issue, as one 
cannot know for certain if the numbers are due to a predominance from one of the 
impediments. Also in creating a combination barrier you broaden the definition, which results 
in a higher likeliness of a subject falling in under this definition - which might be why the 
percentage of subjects with impaired cognitive function and/or language barrier is so high.  
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There should also be a mentioning of the fact that this report does not determine whether the 
patient’s outcome is a result of the impediments hindering them in effective managing of their 
health and disease, as it doesn’t evaluate the progression of the disease in each participant. 
Therefore, this is purely a descriptive survey, that can only serve as a characterisation of the 
barriers based on their frequency and associated consequences. Nevertheless, the results 
suggest that these are widespread barriers to health care, and the findings in this report should 
still serve as an encouragement to further research on the barriers to care and to what extent 
they interfere with effective management of the disease. 
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Conclusion 
In conclusion, the five different barriers to effective health care in CHF patients that are 
reviewed in this report can all be described as common and widespread. The five barriers 
reviewed were living remote from health care services, age in the upper quartile (83+), 
cognitive impairment and/or language barrier, living alone, NYHA class III or IV. 
Additionally, they all constitute a potential threat in the worsening of the condition due to 
their possible hindrance to effective treatment and management, and there are therefore a 
number of likely consequences associated with the presence of one or a combination of the 
barriers. In some of the barriers there can also be described different levels of severity in 
regards to which extent a patient is affected. All of these characteristics needs to be taken into 
account when evaluating the requirements that need to be met for each individual CHF case. 
	
Desired prospects 
 
Currently CHF remains one of the most mortal and disabling of CVD states (4), and even 
though there are currently established various CHF-MP there is still an obvious room for 
improvement. By understanding the likely hindrances a CHF patient may face in the 
managing of their disease, you also develop an understanding on how to overcome these 
barriers. Moreover, by describing and thereby putting a character to each barrier, you develop 
a way of recognising the barriers in the patients. With further analysis of an even broader 
spectre of barriers to effective health care in CHF patients, we could give a more effective and 
successful managing of the disease, that to a greater extent recognizes and deals with the 
complexity and diversity of each individual case.  
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